Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Open access
Rebecca, Vito W., Nicastri, Michael C., McLaughlin, Noel, Fennelly, Colin, McAfee, Quentin, Ronghe, Amruta, Nofal, Michel, Lim, Chun-Yan, Witze, Eric, Chude, Cynthia I., Zhang, Gao, Alicea, Gretchen M., Piao, Shengfu, Murugan, Sengottuvelan, Ojha, Rani, Levi, Samuel M., Wei, Zhi, Barber-Rotenberg, Julie S., Murphy, Maureen E., Mills, Gordon B., Lu, Yiling, Rabinowitz, Joshua, Marmorstein, Ronen, Liu, Qin, Liu, Shujing, Xu, Xiaowei, Herlyn, Meenhard, Zoncu, Roberto, Brady, Donita C., Speicher, David W., Winkler, Jeffrey D., Amaravadi, Ravi K.·2017·Cancer Discovery

Abstract

Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (i.e., autophagy and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial compounds such as chloroquine or quinacrine have been used as lysosomal inhibitors, but fail to inhibit mTOR signaling. Further, the molecular target of these agents has not been identified. We report a screen of novel dimeric antimalarials that identifies dimeric quinacrines (DQ) as potent anticancer compounds, which concurrently inhibit mTOR and autophagy. Central nitrogen methylation of the DQ linker enhances lysosomal localization and potency. An in situ photoaffinity pulldown identified palmitoyl-protein thioesterase 1 (PPT1) as the molecular target of DQ661. PPT1 inhibition concurrently impairs mTOR and lysosomal catabolism through the rapid accumulation of palmitoylated proteins. DQ661 inhibits the in vivo tumor growth of melanoma, pancreatic cancer, and colorectal cancer mouse models and can be safely combined with chemotherapy. Thus, lysosome-directed PPT1 inhibitors represent a new approach to concurrently targeting mTORC1 and lysosomal catabolism in cancer. Significance: This study identifies chemical features of dimeric compounds that increase their lysosomal specificity, and a new molecular target for these compounds, reclassifying these compounds as targeted therapies. Targeting PPT1 blocks mTOR signaling in a manner distinct from catalytic inhibitors, while concurrently inhibiting autophagy, thereby providing a new strategy for cancer therapy. Cancer Discov; 7(11); 1266–83. ©2017 AACR. See related commentary by Towers and Thorburn, p. 1218. This article is highlighted in the In This Issue feature, p. 1201

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0741

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 209

Metadata

Authors
Rebecca, V. W., Nicastri, M. C., McLaughlin, N., Fennelly, C., McAfee, Q., Ronghe, A., Nofal, M., Lim, C.-Y., Witze, E., Chude, C. I., Zhang, G., Alicea, G. M., Piao, S., Murugan, S., Ojha, R., Levi, S. M., Wei, Z., Barber-Rotenberg, J. S., Murphy, M. E., Mills, G. B., Lu, Y., Rabinowitz, J., Marmorstein, R., Liu, Q., Liu, S., Xu, X., Herlyn, M., Zoncu, R., Brady, D. C., Speicher, D. W., Winkler, J. D., & Amaravadi, R. K.
Venue
Cancer Discovery
Published
2017-11-01
Volume
7
Issue
11
Pages
1266-1283
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2755560018
Cited by
209
References
14
FWCI
14.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0741
The paper
Rebecca, V. W., Nicastri, M. C., McLaughlin, N., Fennelly, C., McAfee, Q., Ronghe, A., Nofal, M., Lim, C.-Y., Witze, E., Chude, C. I., Zhang, G., Alicea, G. M., Piao, S., Murugan, S., Ojha, R., Levi, S. M., Wei, Z., Barber-Rotenberg, J. S., Murphy, M. E., . . . Amaravadi, R. K. (2017). A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0741

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.